The C Reactive Protein Testing Market is growing as healthcare providers increasingly use CRP testing to evaluate inflammation and support the management of chronic health conditions. The market was valued at approximately USD 3.196 billion in 2024 and is projected to reach USD 6.66 billion by 2035, expanding at a 6.9% CAGR during 2025–2035.

Technological advancements are improving the speed, accuracy, and accessibility of CRP testing. High-sensitivity assays, automated laboratory systems, and point-of-care testing solutions are helping healthcare professionals obtain useful results more efficiently. These developments are supporting broader adoption across hospitals, diagnostic laboratories, clinics, and other healthcare settings.

By assay type, Chemiluminescence Immunoassay (CLIA) represents the largest segment, while Enzyme-linked Immunosorbent Assay (ELISA) is experiencing rapid growth. By application, cardiovascular disease accounts for the largest share, whereas rheumatoid arthritis is identified as a fast-growing area due to increasing awareness of inflammatory and autoimmune conditions.

North America currently leads the market, supported by advanced healthcare infrastructure, diagnostic technology adoption, and clinical research activity. Asia-Pacific is expected to record the fastest growth as healthcare infrastructure expands and demand for diagnostic services increases. Future opportunities are likely to come from point-of-care testing, AI-supported data analysis, preventive healthcare, and wider access to CRP testing in emerging markets.

Understand industry shifts with well-researched analysis:

Liquid Biopsy Market Volume

Liquid Biopsy Market Forecast

Liquid Biopsy Market Outlook

Liquid Biopsy Market Analysis

Active Adult Community Market Distribution